News

Precigen shares jump after U.S. FDA approves first therapy for rare respiratory disease

Precigen's Papzimeos wins FDA approval for rare respiratory disease, offering hope for patients with recurrent surgeries.
MyChesCo on MSN16h

FDA Approves First Immunotherapy for Rare Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba), marking the first approved ...